Why did Cencora raise its fiscal 2026 EPS guidance?

Management cited strong third-quarter performance and confidence in the outlook. The raise also reflects the earlier-than-planned completion of $1 billion in share repurchases, which lowers the share count. The increase is modest, from $17.70-$17.90 to $17.75-$17.95 (a $0.05 raise at each end).

How much did the OneOncology acquisition contribute to results?

The acquisition, completed February 2, 2026, was the primary driver of higher gross profit and operating expenses in U.S. Healthcare Solutions. Gross margin in that segment improved, and the company cited it as a key reason for the increase in segment operating income. The release does not quantify the acquisition's standalone revenue or earnings contribution.

Is the higher debt load a concern for investors?

Interest expense is rising sharply, with net interest expense up $58.9 million year-over-year in the quarter. Total debt increased from about $7.7 billion at September 30, 2025 to about $11.7 billion at June 30, 2026. Management's guidance calls for roughly $490 million of net interest expense for fiscal 2026, compared with $292 million in fiscal 2025. Investors should monitor leverage and whether earnings growth keeps pace with the higher financing costs.

What are the main quality-of-earnings considerations in the GAAP results?

GAAP results include several items that affect comparability, including a $102.0 million opioid liability reduction, a $94.3 million LIFO credit, and $5.5 million of antitrust settlement gains. Adjusted results exclude these items along with acquisition amortization and deal costs. Management also noted that GLP-1 sales, which carry lower margins, weighed on gross margin. Investors should weigh the adjusted and GAAP figures together, since GAAP EPS of $3.94 is about 12% below adjusted EPS of $4.48.

COR 8-K: Earnings & Results & Regulation FD

01—Abstract

Summary

Summary of the 8-K filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.

Cencora (COR) reported fiscal Q3 2026 (quarter ended June 30, 2026) with revenue of $84.8 billion^a, up 5.1% year-over-year, and GAAP diluted EPS of $3.94 versus $3.52 a year earlier (up 11.9%).

Adjusted diluted EPS rose 12.0% to $4.48^b. Growth was driven by the February 2026 OneOncology acquisition and strong U.S. Healthcare Solutions unit volume, including specialty and GLP-1 products, partly offset by lower brand manufacturer pricing and the 2025 loss of an oncology customer. Adjusted operating income grew 17.0% to $1.24 billion, and the adjusted operating margin expanded 15 basis points to 1.46%.

A $102.0 million^c reduction in opioid liability, tied to the dismissal of opioid litigation, flattered GAAP operating expenses in the quarter. Management raised fiscal 2026 adjusted diluted EPS guidance to $17.75-$17.95 from $17.70-$17.90, citing strong performance and the completion of $1 billion in opportunistic share repurchases, which had been planned for calendar 2026. Net interest expense rose 72% to $141 million as the company financed OneOncology with $3.0 billion of senior notes and $1.5 billion of term loans.

Total debt, including short- and long-term debt, rose to roughly $11.7 billion^d from about $7.7 billion at fiscal year-end 2025, and stockholders' equity increased to $3.24 billion. The board also declared a $0.60 quarterly dividend payable August 31, 2026.

The update is generally constructive: earnings beat expectations on an adjusted basis, the guidance raise is modest, and the acquisition is contributing to growth. Investors should watch the higher leverage and interest burden, the margin pressure from lower-margin GLP-1 sales, and the mix of one-time items in GAAP results, which include a $1.1 billion nine-month remeasurement gain on OneOncology.

02—Key points

Key Highlights

Q3 FY2026 revenue rose 5.1% year-over-year to $84.8 billion, with U.S. Healthcare Solutions up 4.9% and International Healthcare Solutions up 5.9%.
GAAP diluted EPS was $3.94 (up 11.9%); adjusted diluted EPS was $4.48 (up 12.0%) versus $4.00 a year earlier.
Fiscal 2026 adjusted diluted EPS guidance raised to $17.75-$17.95 from $17.70-$17.90; adjusted operating income guidance is 13%-14% growth.
Completed $1.0 billion of share repurchases in the quarter, pulling forward a plan originally expected to finish by end of calendar 2026; diluted shares fell 0.7% to 193.9 million.
Adjusted operating income rose 17.0% to $1.24 billion, with adjusted operating margin up 15 basis points to 1.46%, aided by the OneOncology acquisition.
Net interest expense rose 72% to $141 million following $3.0 billion of senior notes and $1.5 billion of term loans issued to fund OneOncology, raising leverage.
GAAP results include a $102.0 million opioid liability reduction; quarterly dividend of $0.60 per share declared, payable August 31, 2026.

03—Questions

Frequently Asked Questions

Why did Cencora raise its fiscal 2026 EPS guidance?
Management cited strong third-quarter performance and confidence in the outlook. The raise also reflects the earlier-than-planned completion of $1 billion in share repurchases, which lowers the share count. The increase is modest, from $17.70-$17.90 to $17.75-$17.95 (a $0.05 raise at each end).
How much did the OneOncology acquisition contribute to results?
The acquisition, completed February 2, 2026, was the primary driver of higher gross profit and operating expenses in U.S. Healthcare Solutions. Gross margin in that segment improved, and the company cited it as a key reason for the increase in segment operating income. The release does not quantify the acquisition's standalone revenue or earnings contribution.
Is the higher debt load a concern for investors?
Interest expense is rising sharply, with net interest expense up $58.9 million year-over-year in the quarter. Total debt increased from about $7.7 billion at September 30, 2025 to about $11.7 billion at June 30, 2026. Management's guidance calls for roughly $490 million of net interest expense for fiscal 2026, compared with $292 million in fiscal 2025. Investors should monitor leverage and whether earnings growth keeps pace with the higher financing costs.
What are the main quality-of-earnings considerations in the GAAP results?
GAAP results include several items that affect comparability, including a $102.0 million opioid liability reduction, a $94.3 million LIFO credit, and $5.5 million of antitrust settlement gains. Adjusted results exclude these items along with acquisition amortization and deal costs. Management also noted that GLP-1 sales, which carry lower margins, weighed on gross margin. Investors should weigh the adjusted and GAAP figures together, since GAAP EPS of $3.94 is about 12% below adjusted EPS of $4.48.

04—Continue

← View all 8-K filings